SMYD3 (D2Q4V) Rabbit mAb

• 产品编号：CST-12859S      品牌：CST       原厂货号：12859S
• 产品分类：抗体 > 一抗 > 蛋白特异性一抗
• 应用分类：

描述：

SMYD3 (D2Q4V) Rabbit mAb 兔单抗能够检测内源性SMYD3总蛋白。该抗体不会与其他SMYD蛋白发生交叉反应。此单克隆抗体是经由采用合成的与人源 MYD3蛋白的Pro357残基周围序列相对应的肽段免疫动物而生产的。SET and MYND domain containing protein 3 (SMYD3)是含SET结构域的蛋白甲基转移酶家族的成员，定位于核和胞质内（1-3）。已经确认了几种SMYD3的底物；但是数据仍存在争议。在一个研究中，SMYD3 能够甲基化组蛋白 H3的Lys4位点（二，三甲基化都有），并且能够与RNA聚合酶相互作用激活转录（1）。 第二个研究表明，SMYD3优先甲基化组蛋白H4 Lys20位点，能够与nuclear receptor corepressor complex (NCOR)相互作用从而阻遏转录（2）。 第三个研究显示，SMYD3优先甲基化组蛋白H4 Lys5位点（单，二，三甲基化）（3）。此外，SMYD3还能够甲基化endothelial growth factor receptor 1 (VEGFR1)的Lys831位点，并激活其激酶活性（4）。不论蛋白底物的优先性如何，有一点非常清楚就是，SMYD3的功能是癌基因。研究已经表明SMYD3 在肝癌，乳腺癌以及直肠癌中高度过表达。在多种细胞系中过表达的SMYD3会增强其增殖，粘附以及迁移，而降低表达水平会产生明显的细胞生长抑制（1,5-10）。此外，在多种癌细胞系表达全长SMYD3和缺失N-末端 34个氨基酸的截短型SMYD3，结果显示截短型对组蛋白H3的甲基转移酶活性升高（11）。

1. Hamamoto, R. et al. (2004) Nat Cell Biol 6, 731-40.
2. Foreman, K.W. et al. (2011) PLoS One 6, e22290.
3. Van Aller, G.S. et al. (2012) Epigenetics 7, 340-3.
4. Kunizaki, M. et al. (2007) Cancer Res 67, 10759-65.
5. Luo, X.G. et al. (2007) J Biosci Bioeng 103, 444-50.
6. Wang, S.Z. et al. (2008) BMB Rep 41, 294-9.
7. Zou, J.N. et al. (2009) Cancer Lett 280, 78-85.
8. Luo, X.G. et al. (2009) IUBMB Life 61, 679-84.
9. Luo, X.G. et al. (2010) IUBMB Life 62, 194-9.
10. Ren, T.N. et al. (2011) Med Oncol 28 Suppl 1, S91-8.
11. Silva, F.P. et al. (2008) Oncogene 27, 2686-92.

原厂资料：

Specificity / Sensitivity

SMYD3 (D2Q4V) Rabbit mAb recognizes endogenous levels of total SMYD3 protein. This antibody does not cross-react with other SMYD proteins.

Source / Purification

Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Pro357 of human SMYD3 protein.

Background

SET and MYND domain containing protein 3 (SMYD3) is a member of the SET domain-containing family of protein methyltransferases and is localized to both the nucleus and cytoplasm (1-3). Several histone substrates have been identified for SMYD3; however, the data is controversial. In one study, SMYD3 has been shown to methylate histone H3 Lys4 (both di- and tri-methylation) and interact with RNA polymerase II to activate transcription (1). A second study has shown that SMYD3 preferentially methylates histone H4 Lys20 and interacts with nuclear receptor corepressor complex (NCOR) to repress transcription (2). A third study has shown that SMYD3 preferentially methylates histone H4 Lys5 (mono-, di-, and tri-methylation) (3). In addition, SMYD3 has been shown to methylate the endothelial growth factor receptor 1 (VEGFR1) on Lys831 and stimulate its kinase activity (4). Regardless of the preferred protein substrates, it is clear that SMYD3 functions as an oncogene. Research studies have shown SMYD3 is highly over-expressed in liver, breast, and rectal carcinomas. Over-expression of SMYD3 in multiple cell lines enhances proliferation, adhesion, and migration, while reduced expression results in significant suppression of cell growth (1,5-10). In addition, multiple cancer cell lines express both full length SMYD3 and a cleaved form of SMYD3 lacking the N-terminal 34 amino acids, and the cleaved form shows increased methyltransferase activity toward histone H3 (11).

1. Hamamoto, R. et al. (2004) Nat Cell Biol 6, 731-40.
2. Foreman, K.W. et al. (2011) PLoS One 6, e22290.
3. Van Aller, G.S. et al. (2012) Epigenetics 7, 340-3.
4. Kunizaki, M. et al. (2007) Cancer Res 67, 10759-65.
5. Luo, X.G. et al. (2007) J Biosci Bioeng 103, 444-50.
6. Wang, S.Z. et al. (2008) BMB Rep 41, 294-9.
7. Zou, J.N. et al. (2009) Cancer Lett 280, 78-85.
8. Luo, X.G. et al. (2009) IUBMB Life 61, 679-84.
9. Luo, X.G. et al. (2010) IUBMB Life 62, 194-9.
10. Ren, T.N. et al. (2011) Med Oncol 28 Suppl 1, S91-8.
11. Silva, F.P. et al. (2008) Oncogene 27, 2686-92.

注意事项：

Storage: Supplied in 10 mM sodium HEPES (pH 7.5), 150
mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02%
sodium azide. Store at –20°C. Do not aliquot the antibody.